

In re Application of:  
Grotendorst and Neff  
Application No.: 10/658,856  
Filed: September 9, 2003  
Page 2 of 10

PATENT  
Atty Docket No.: FIBRO1130-3

**Amendments to the Claims**

Please amend claim 15 as indicated in the listing of claims.

Please add new claim 37.

Please cancel claims 16-18 and 24-36 without prejudice or disclaimer.

The listing of claims will replace all prior versions, and listings of claims in the application.

**Listing of Claims:**

1.-14. (Canceled).

15. (Currently amended) An isolated antibody that specifically binds to a C-terminal fragment of connective tissue growth factor (CTGF) polypeptide ~~comprising the amino acid sequence of SEQ ID NO:4~~, wherein the antibody inhibits DNA synthesis, and wherein the C-terminal fragment of CTGF consists of an amino acid sequence selected from the group consisting of:

- (a) residue 4 through 74 of SEQ ID NO:4; or
- (b) residue 75 through 172 of SEQ ID NO:4; or
- (c) residue 4 through 172 of SEQ ID NO:4.

16.-18. (Canceled).

19. (Original) The antibody of claim 15, wherein the antibody is a monoclonal antibody.

20. (Original) The antibody of claim 19, wherein the antibody is a human monoclonal antibody.

In re Application of:  
Grotendorst and Neff  
Application No.: 10/658,856  
Filed: September 9, 2003  
Page 3 of 10

PATENT  
Atty Docket No.: FIBRO1130-3

21. (Original) The antibody of claim 15, wherein the antibody is a polyclonal antibody.
22. (Currently amended) The antibody of claim 15, wherein the antibody comprises murine antigen binding region residues ~~and human antibody residues~~.
23. (Original) A composition comprising the antibody of claim 15 and a pharmaceutically acceptable excipient or carrier.
- 24.-36. (Canceled).
37. (New) The antibody of claim 18, wherein the antibody comprises human antibody residues.